Literature DB >> 20336495

Comparison of humanized IgG and FvFc anti-CD3 monoclonal antibodies expressed in CHO cells.

Flavia Serpieri1, Andre Inocencio, Jose Marcelino de Oliveira, Alécio A Pimenta, Angélica Garbuio, Jorge Kalil, Marcelo M Brigido, Ana Maria Moro.   

Abstract

Two humanized monoclonal antibody constructs bearing the same variable regions of an anti-CD3 monoclonal antibody, whole IgG and FvFc, were expressed in CHO cells. Random and site-specific integration were used resulting in similar expression levels. The transfectants were selected with appropriate selection agent, and the surviving cells were plated in semi-solid medium for capture with FITC-conjugated anti-human IG antibody and picked with the robotic ClonePix FL. Conditioned media from selected clones were purified by affinity chromatography and characterized by SDS-PAGE, Western-blot, SEC-HPLC, and isoelectric focusing. Binding to the target present in healthy human mononuclear cells was assessed by flow cytometry, as well as by competition between the two constructs and the original murine monoclonal antibody. The humanized constructs were not able to dislodge the murine antibody while the murine anti-CD3 antibody could dislodge around 20% of the FvFc or IgG humanized versions. Further in vitro and in vivo pre-clinical analyses will be carried out to verify the ability of the humanized versions to demonstrate the immunoregulatory profile required for a humanized anti-CD3 monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20336495     DOI: 10.1007/s12033-010-9269-2

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  12 in total

1.  Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen.

Authors:  C Caldas; V P Coelho; D J Rigden; G Neschich; A M Moro; M M Brígido
Journal:  Protein Eng       Date:  2000-05

Review 2.  Antibody humanization: a case of the 'Emperor's new clothes'?

Authors:  M Clark
Journal:  Immunol Today       Date:  2000-08

3.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Authors:  Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

Review 4.  Antibody engineering and modification technologies.

Authors:  David Filpula
Journal:  Biomol Eng       Date:  2007-03-31

Review 5.  Selective immunosuppression with anti-T cell monoclonal antibodies.

Authors:  L Chatenoud; J F Bach
Journal:  Clin Nephrol       Date:  1992       Impact factor: 0.975

6.  Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.

Authors:  Hernandez M Silva; Pedro M M M Vieira; Patricia L N Costa; Bárbara M S Pimentel; Ana M Moro; Jorge Kalil; Andrea Q Maranhão; Verônica Coelho; Marcelo M Brigido
Journal:  Immunol Lett       Date:  2009-06-30       Impact factor: 3.685

7.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

8.  A randomized prospective trial of OKT3 induction in the current immunosuppression era.

Authors:  M L Henry; R P Pelletier; E A Elkhammas; G L Bumgardner; E A Davies; R M Ferguson
Journal:  Clin Transplant       Date:  2001-12       Impact factor: 2.863

9.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

10.  A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.

Authors: 
Journal:  N Engl J Med       Date:  1985-08-08       Impact factor: 91.245

View more
  4 in total

1.  Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Authors:  Thomas Spreter Von Kreudenstein; Eric Escobar-Carbrera; Paula I Lario; Igor D'Angelo; Karine Brault; John Kelly; Yves Durocher; Jason Baardsnes; R Jeremy Woods; Michael Hongwei Xie; Pierre-Alain Girod; Michael D L Suits; Martin J Boulanger; David K Y Poon; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

2.  A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.

Authors:  Mateus Dalcin Luchese; Mariana Lopes Dos Santos; Angelica Garbuio; Roselaine Campos Targino; Carla Ploeger Mansueli; Lilian Rumi Tsuruta; Wagner Quintilio; Ana Maria Moro
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

3.  An automated system for high-throughput single cell-based breeding.

Authors:  Nobuo Yoshimoto; Akiko Kida; Xu Jie; Masaya Kurokawa; Masumi Iijima; Tomoaki Niimi; Andrés D Maturana; Itoshi Nikaido; Hiroki R Ueda; Kenji Tatematsu; Katsuyuki Tanizawa; Akihiko Kondo; Ikuo Fujii; Shun'ichi Kuroda
Journal:  Sci Rep       Date:  2013-02-01       Impact factor: 4.379

4.  Advances in Mammalian cell line development technologies for recombinant protein production.

Authors:  Tingfeng Lai; Yuansheng Yang; Say Kong Ng
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.